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ABSTRACT 
 
Tubedown (Tbdn) is a retinal homeostatic factor which is normally highly 
expressed in the retinal blood vessels which associates with the N-acetyltransferase Ard1. 
Tbdn also associates with Cortactin, a c-Src tyrosine kinase substrate. Downregulation of 
Tbdn correlates with neovascular retinal pathology in neovascular retinopathies. These 
diseases involve growth and hyperpermeability of retinal blood vessels leading to leakage 
of plasma proteins such as Albumin, inflammation and tissue damage.  Knockdown of 
Tbdn in retinal endothelial cells results in co-suppression of Ard1, activation of c-Src/Fyn 
tyrosine kinase and increased permeability to Albumin. The focus of this study is to 
determine how Ard1 might regulate signaling pathways mediating the permeability of 
endothelial cells to Albumin as well as levels of phospho-Cortactin Tyr421 and activated 
c-Src/Fyn. 
Ard1 was either knocked down using siRNA or overexpressed in RF/6A primate 
retinal endothelial cell line and the permeability to Albumin assayed. In parallel 
experiments, the activation status of components of the Albumin permeability pathway 
(phospho-Cortactin Tyr 421 and activated c-Src/Fyn) was monitored. 
Ard1 knockdown reduced the permeability of the cells to FITC-Albumin but did 
not change the levels of phospho-Cortactin Tyr 421 or activated c-Src/Fyn when 
compared to controls. Cells transfected with the Ard1 expression vector overexpressed 
Ard1 and showed increased permeability of Albumin and increased levels of activated c-
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Src/Fyn compared to controls. Our results suggest that Ard1-mediated increase of 
activated c-Src/Fyn does not require Tbdn.  
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Chapter 1 Introduction 
1.1 The Visual System 
1.1.1 The Eye 
Vision is an important sense which allows us to perceive the world around us.  
Loss of vision may result in a loss of functional autonomy and depression in affected 
individuals. Light waves enter the eye through the cornea through an opening in the iris 
known as the pupil. The iris controls the diameter of the pupil and the amount of light that 
enters the eye (Davson and Perkins, 2014). These light rays then pass through the lens 
which is a structure that, along with the cornea, can refract light which will then focus on 
the retina. Before reaching the retina the light rays also pass through a gelatinous 
substance called the vitreous body (Davson and Perkins, 2014). The light rays then focus 
on the point of highest visual acuity in the retina, the fovea. The fovea is located within 
the macula and contains a high density of cones. The avascular fovea is responsible for 
clear central vision (Davson and Perkins, 2014). 
1.1.2 The Retina 
 The retina is a thin delicate tissue located in the inner layer of the globe of the eye. 
Located between the vitreous body and the retinal pigment epithelium (RPE), it consists 
of eight different layers. The nerve fiber layer (NFL) is located above the ganglion cell 
layer (GCL), followed by the inner plexiform layer (IPL) which contains the synapses 
between the bipolar cells and the ganglion cells (Bergman et al., 2014). The inner nuclear 
layer contains the nuclei of the bipolar cells. The outer plexiform layer (OPL) contains 
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the synapses between the rods and cones and the bipolar cells. Finally, the outer nuclear 
layer (ONL) consists of the cell bodies of the photoreceptors (Bergman et al., 2014). 
Beneath the photoreceptors lies the RPE (Bergman et al., 2014). Light rays pass through 
the ganglion cell layer and the bipolar cell layer to reach the photoreceptors. There are 
two types of photoreceptors; rods, which function in low light conditions and cones, 
which are responsible for color vision. The outer segments of the photoreceptors are 
composed of stacks of membranes which contain the visual pigment molecules required 
for vision. The photoreceptor outer segments experience photo-oxidative damage and 
they are maintained by the RPE (Strauss, 2014). The inner segments of the photoreceptors 
contain mitochondria and ribosomes and are responsible for the metabolism of the outer 
segments (Kolb, 2014). The photoreceptors transmit the signal to the bipolar cells, 
followed by transmission to the ganglion cells. There are both rod bipolar cells and cone 
bipolar cells. Cone bipolar cells can be divided into two types: OFF bipolar cells which 
are hyperpolarized by central illumination and ON bipolar cells which are depolarized by 
central illumination (Nelson and Connaughton, 2014). In humans, they have further 
differentiated cone bipolar cells into two types: midget bipolar cells, which contact one 
cone, and diffuse bipolar cells which interact with multiple cones (Wassle and Boycott, 
1991). The differing connectivity with photoreceptors can result in variation of the 
functional outcomes of the visual pathway. Beneath the photoreceptors lies the RPE. The 
RPE contains pigment granules and has roles in light absorption and epithelial transport 
(Strauss, 2014). The axons of the ganglion cells converge to form the optic nerve where 
the visual signals leave the eye. These signals will travel to the visual cortex, where the 
information can be interpreted by the brain (Nelson, 2014). The blind spot of the retina is 
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due to the fact that there are no photoreceptors on the optic disc, which is where the optic 
nerve leaves the eye (Gamm, 2014).  
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Figure 1: (A) Anatomy of the human eye (a public domain image from (Anonymous). 
(B) Hematoxylin & Eosin staining of the mouse retina.  
The retina consist of eight different layers. Beginning at the vitreous (V) the layers are as 
follows: nerve fiber layer (NFL), ganglion cell layer (GCL), inner plexiform layer (IPL), 
inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), 
photoreceptors and the retinal pigment epithelium (RPE). The ONL contains the cell 
bodies of the photoreceptors. The choroid circulation supplies the avascular outer-retina. 
The outer layer of the eye is the sclera (S). Magnification: 10X.  
http://www.wpclipart.com/medical/anatomy/eye/eye_diagram.png.html  
 
1.2 Retinal Vasculature 
There are two vascular supplies in the retina; intra-retinal blood vessels which 
supply the inner two-thirds of the retina while the choroidal circulation supplies the 
photoreceptors located in the avascular outer one-third of the retina (Kur et al., 2012). 
The central retinal artery enters the eye through the optic disc and branches into the 
retinal arteries. Endothelial cells with tight junctional complexes line the interior of the 
retinal blood vessels (Kur et al., 2012). The retinal blood vessels contain layers of smooth 
muscle which comprise the tunica media. Endothelial cells within the tunica intima line 
the interior of blood vessels and their tight junctions control the passage of solute from 
the lumen of the blood vessels to the interstitial space. Pericytes are contractile cells 
which surround the endothelial cells of capillaries. Their functions include regulation of 
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blood flow through capillaries as well as roles in angiogenesis and maintenance of normal 
blood vessels (Sims, 1986).  Studies have shown that a variety of growth factors may be 
involved in recruitment of pericytes in blood vessels. These factors include growth factors 
such as vascular endothelial growth factor (VEGF), platelet-derived growth factor B 
(PDGF-B), transforming growth factor β (TGF-β) and their receptors as well as 
angiopoietin-1 and its receptor, the tyrosine kinase Tie-2 (Hammes, 2005). The retinal 
blood vessels have a much higher pericyte coverage (94.5%) than those of the choroid 
(11.5%; (Chan-Ling et al., 2011).  The choroid vasculature is supplied by the long and 
short ciliary arteries. The choroid is composed of 5 layers, Bruch’s membrane, three 
vascular layers (the choriocapillaries, Sattler’s layer and Haller’s layer) and the 
suprachoroidea (Kur et al., 2012). Haller’s layer contains large arteries and veins while 
Sattler’s layer contains medium and small arterioles that nourish the choriocapillaries. 
The blood vessels of the choroid are fenestrated, which means the endothelial cells 
contain small pores through which molecules can pass (Tornquist et al., 1990).  
 
1.3 Vascular Permeability 
A monolayer of endothelial cells known as the vascular endothelium lines blood 
vessels. The tunica intima layer consists of vascular endothelium, basement membrane 
and sometimes an internal elastic lamina which also play a role in the barrier function of 
blood vessels. The vascular endothelium, together with vascular smooth muscle cells, can 
regulate angiogenesis, smooth muscle tone and tissue fluid homeostasis (Mehta and 
Malik, 2006). Generally, the endothelial barrier is controlled by inflammatory cells and 
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mural cells, transcellular transport and by intercellular junctions via paracellular 
permeability (Goddard and Iruela-Arispe, 2013). Mural cells include pericytes and 
smooth muscle cells. The vascular endothelium is semi-permeable and can transport large 
molecules and fluid from the lumen of the blood vessels to the interstitial space. Plasma 
proteins in the blood are at a higher concentration within the vessels than in the interstitial 
space (Mehta and Malik, 2006). In general, molecules smaller than 3nm molecular radius 
(Mr) cross the endothelium through the paracellular pathway while molecules greater than 
3nm Mr as well as water cross the endothelium by the transcellular pathway. Albumin, 
which is the most abundant of the plasma proteins, crosses the vascular endothelium 
under normal conditions via the transcellular pathway (Mehta and Malik, 2006). 
Extracellular matrix (ECM) proteins which lie beneath the vascular endothelium play a 
role in its barrier function. The endothelial cell layer regulates transport of albumin, thus 
it also regulates the transendothelial oncotic pressure gradient. Endothelial cells are 
connected by junctional proteins which make up adherens junctions, tight junctions and 
gap junctions. Adherens junctions are composed of vascular endothelial (VE)-Cadherin, 
while tight junctions are formed from claudins, occludin as well as junctional adhesion 
molecules (JAM) (Mehta and Malik, 2006). Gap junctions are composed of 
transmembrane hydrophilic proteins called connexins (Stout et al., 2004). Vascular 
permeability can be regulated by thrombin, histamine, bradykinin and VEGF. VEGF 
causes an increase in both paracellular and transcellular permeability. Paracellular 
permeability is the transit of solutes between the cells via interendothelial junctions while 
transcellular permeability is transit of solutes through the cells via caveolae-mediated 
transport (Mehta and Malik, 2006). Initially, VEGF binds the fms-like tyrosine kinase 
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(Flt-1) receptor which results in an increase in vascular permeability (Mehta and Malik, 
2006). Specifically, VEGF treated bovine retinal microvascular cells caused a significant 
increase in permeability of albumin across a cell monolayer (Chang et al., 2000).   
Endothelial cell permeability can also be regulated by Src family of kinases. Src  
phosphorylates dynamin and caveolin which are required for caveolar endocytosis (Mehta 
and Malik, 2006). Transcellular transport of albumin is dependent on endocytosis of 
albumin bound to the 60-kDa glycoprotein receptor (gp60). Albumin binds gp60 which is 
a required step in albumin transcytosis. gp60 then activates Src through activation of the 
βγ subunit of Gi (Mehta and Malik, 2006). This is followed by Src-dependent tyrosine 
phosphorylation of dynamin-2, which interacts with caveolin-1 to initiate caveolae 
mediated endocytosis and transport of albumin (Shajahan et al., 2004). 
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Figure 2: Schematic of caveolar endocytosis and transport of albumin. 
(A) Albumin binds gp60 which is a required step in albumin transcytosis. gp60 then 
activates Src through activation of the βγ subunit of Gi. (B) This is followed by 
phosphorylated Src (P-Src)-dependent tyrosine phosphorylation of dynamin-2, which 
interacts with caveolin-1 to initiate caveolae mediated endocytosis and transport of 
albumin. 
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1.4 Neovascular Retinopathies 
Neovascular retinopathies are characterized by growth of abnormal blood vessels 
in the retina which can lead to vision loss. Visually impaired people have a higher 
incidence of depression than people with normal vision (Evans et al., 2007). A possible 
reason for this higher incidence of depression could be the loss of independence that often 
occurs when one loses their vision as well as adverse side effects from treatment. One 
example of a neovascular retinopathy, Age-related macular degeneration (AMD), has 
been reported to be the leading cause of blindness in the aged population in developed 
countries and also the third leading cause of blindness worldwide (Resnikoff et al., 2004). 
AMD can occur in both dry and wet forms.  Consequences of the dry form of AMD 
include the appearance of drusen deposits between Bruch’s membrane and the retinal 
pigment epithelium located in the macula (Ambati et al., 2003). Drusen are yellow or 
white deposits of lipids and are a common early sign of dry AMD. Accumulation of 
drusen can lead to geographic atrophy of RPE cells and death of the photoreceptors 
(Green and Key, 2005). AMD also consists of thickening of Bruch’s membrane as well as 
hyper and hypopigmentation of RPE and cell death, which leads to vision loss (Green, 
1999). The dry form of AMD can be asymptomatic with the possibility of developing into 
wet AMD. The wet or exudative form of AMD involves neovascularisation of the 
choroidal blood vessels which can either remain beneath the RPE or pass through Bruch’s 
membrane and the RPE to enter the neural retina (Ambati et al., 2003). The more 
aggressive classic type of choroidal neovascularization (CNV) is often associated with 
early and substantial vision loss due to loss of photoreceptors while the less severe occult 
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type of CNV are present with long term maintenance of vision until deterioration of the 
RPE occurs (Bressler et al., 1990;Schmidt-Erfurth et al., 2007). Topographic angiography 
showed that classic CNV appeared as a well-demarcated lesions with steep, craterlike 
borders, frequently surrounded by a halo, which suggests leakage of choroidal blood 
vessels and perfusion changes (Schmidt-Erfurth et al., 2007). Occult CNV was 
documented by topographic angiography as a convex lesion with flat, ill-defined borders 
and intraretinal leakage which is most likely less pronounced that classic CNV (Schmidt-
Erfurth et al., 2007). These vessels are abnormal because they are hyperpermeable and 
may leak blood and serum proteins such as albumin from the retinal blood vessels to the 
interstitial space. This leakage of albumin can result in inflammation, scarring and 
possible retinal detachment (Ambati et al., 2003;Bonnel et al., 2003).  
Another common cause of vision loss is diabetic retinopathy (DR). There are 
approximately 93 million people globally suffering from DR, specifically 17 million with 
proliferative diabetic retinopathy (PDR; (Yau et al., 2012). DR can be either 
nonproliferative or proliferative in which there is neovascularisation of retinal blood 
vessels. DR involves capillary basement membrane thickening as well as loss of 
endothelial cells and pericytes. This can lead to capillary occlusion as well as 
microaneurysms. In the more advanced PDR, there can be neovascularisation, retinal 
detachment and vision loss (Gardner et al., 2002;Gendron et al., 2001). Hyperglycemia in 
patients with diabetes is thought to be correlated with DR. Several different pathways 
have been proposed to link hyperglycemia to the microvascular complications seen in DR 
patients: Increased polyol pathway flux, increased advanced glycation end-product 
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formation, activation of protein kinase C and increased flux though the hexosamine 
pathway (Hammes, 2005). The polyol pathway metabolizes excess glucose and can result 
in an accumulation of sorbitol. Sorbitol can have damaging effects to retinal cells (Fong 
et al., 2004;Gabbay, 1973).  
Retinopathy of prematurity (ROP) is one of the leading causes of blindness in 
children (Qazi et al., 2009).  Retinas of premature infants are incompletely vascularised 
followed by delayed vascular growth after birth (Smith, 2004). Hypoxia in the peripheral 
areas of the retina causes an increase in VEGF expression and retinal blood vessels grow 
toward the VEGF stimulus (Smith, 2004). Angiogenesis occurs by initial vasodilation of 
existing vessels which is followed by increased permeability as well as degradation of the 
surrounding matrix. Endothelial cells can then migrate and proliferate in order to form 
new blood vessels (Conway et al., 2001). 
Several current treatments for neovascular retinopathies include laser 
photocoagulation and anti-VEGF drugs (Bandello et al., 2013). VEGF is involved in 
increased permeability in animal cells as well as retinal endothelial cells in vitro (Aiello et 
al., 1994). Anti-VEGF drugs are anti-angiogenesis agents which inhibit the function of 
VEGF (Chan et al., 2007). Anti-VEGF drugs such as ranibizumab and bevacizumab have 
been shown to be effective in some patients with AMD (Kanoff and Miller, 2013). 
Bevacizumab is a humanized monoclonal antibody with strong anti-angiogenic activity 
approved by the Food and Drug Administration (FDA) for treatment of colorectal cancer 
in 2005 (McCormack and Keam, 2008). Ranibizumab is a monoclonal antibody fragment 
derived from bevacizumab (Ferrara et al., 2006). While ranibizumab is approved for 
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treatment of neovascular AMD, it is much more expensive than bevacizumab which is 
used “off label” to treat neovascular AMD (Raftery et al., 2007). Recent studies showed 
bevacizumab and ranibizumab had equal effects on visual acuity (CATT Research Group 
et al., 2011;IVAN Study Investigators et al., 2012). Anti-VEGF drugs are also used to 
treat patients with PDR (Bandello et al., 2013).  ROP is normally treated with laser 
ablation of the peripheral retina (Fleck, 2013). However, some patients with AMD do not 
respond to anti-VEGF treatments (Kanoff and Miller, 2013). There have also been reports 
of patients developing RPE tears after being treated with anti-VEGF drugs (Chang et al., 
2007). Several other side effects including inflammation (Georgopoulos et al., 2009), 
retinal ischemia and ocular irritation have also been reported (Wong et al., 2008). New, 
more effective treatments with less risk to the patient are required to help patients 
suffering from AMD, PDR and ROP. In order to develop new treatments, researchers 
must be able to better understand the molecular pathways involved in neovascularisation 
in neovascular retinopathies. 
 
1.5 Arrest Defective-1 and Tubedown  
Arrest Defective-1 (Ard1, also referred to as Naa10) is a 30 kDa N-terminal 
acetyltransferase originally discovered in yeast (Park and Szostak, 1992). In yeast, it 
interacts with a protein known as Tubedown (Tbdn, also referred to as Narg1, NATH, 
Naa15) to form the N-terminal acetyltransferase NatA complex (Park and Szostak, 1992). 
Tbdn has been found to be downregulated during capillary-like formation of IEM 
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embryonic endothelial cells (Gendron et al., 2000). Tbdn is homologous to the yeast Nat1 
N-terminal acetyltransferases (Gendron et al., 2000). The Tbdn protein sequence contains 
tetratricopeptide (TPR) repeats which are known to mediate protein-protein interactions 
(Fig. 2). This suggests that Tbdn may interact with other proteins (Main et al., 
2005;Paradis et al., 2002;Paradis et al., 2008;Willis et al., 2002). There are mammalian 
homologues for Ard1 (Ard2, 81% identity) and Tbdn (mNat2, 70% identity) which have 
been previously described (Arnesen et al., 2006;Sugiura et al., 2003). The NatA complex 
in yeast likely mediates co-translational acetylation of nascent polypeptides from 
ribosomes after initial cleavage of methionine by methionine aminopeptidases (Gautschi 
et al., 2003). The NatA complex also plays roles in cell growth and differentiation 
(Arnesen et al., 2006;Asaumi et al., 2005;Lim et al., 2006;Park and Szostak, 1992).  It has 
also been shown that the putative acetyltransferase Nat5 can interact with NatA and has 
also been reported to interact with Nat1 in the ribosome of yeast (Arnesen et al., 
2006;Gautschi et al., 2003;Hou et al., 2007). A study has shown that the binding of 
Tubedown to Ard1 to form the NatA complex causes a structural change in the active site 
of Ard1 which allows it to acetylate an α-amino group on nascent polypeptide chains with 
N-terminal alanine, cysteine, glycine, serine, threonine or valine (Liszczak et al., 2013). 
This suggests that Tubedown plays a role in regulating activity of Ard1. Ard1 has the 
ability to acetylate lysine residues and potential substrates for this acetylation have been 
reported (Geissenhoner et al., 2004;Kimura et al., 2003;Lim et al., 2006;Polevoda and 
Sherman, 2003;Wang et al., 2004). 
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Ard1 has been reported to acetylate and interact with many different proteins in 
the literature. Ard1 activates the cyclin D1 promoter through activation of Activator 
Protein-1 proteins c-Jun and c-Fos to ultimately increase cellular proliferation (Seo et al., 
2010). Hypoxia-inducible factor 1-alpha (HIF-1α) binds a specific mouse isoform of 
Ard1 and prevents the acetylation of β-catenin (Lim et al., 2008). Ard1 acetylates and 
activates β-catenin promoting lung cancer cell proliferation (Lim et al., 2006). Ard1 can 
also bind the p21-activated kinase (PAK)-interacting exchange factor (PIX) and disrupt 
binding between PIX and G protein-coupled receptor kinase interacting proteins (Hua et 
al., 2011). This prevents the localization of PIX to the plasma membrane, as well as 
inhibits Ras-related C3 botulinum toxin substrate 1 (Rac1) and Cell division control 
protein 42 homolog (cdc42) proteins which are involved in regulation of cell growth 
ultimately inhibiting cellular migration (Hua et al., 2011). Furthermore, Ard1 binds and 
acetylates myosin light chain kinase (MLCK), inactivating it and resulting in reduced 
levels of phosphorylated myosin light chain (MLC) and reduced cell motility (Shin et al., 
2009). Ard1 can also acetylate Tuberous sclerosis protein 2 and reduce mammalian target 
of rapamycin (mTOR) activity leading to autophagy (Kuo et al., 2010). Ard1 interacts 
with DNA methyltransferase which silences the E-cadherin tumour suppressor promoter 
by methylation (Lee et al., 2010). Ard1 is overexpressed in several types of cancer 
including breast, lung and colorectal cancer (Yu et al., 2009). Currently, the NatA 
complex is a possible attractive target for cancer treatment. 
Tbdn is expressed during embryogenesis and is regulated during the 
differentiation of vascular and neuronal tissues (Gendron et al., 2001;Sugiura et al., 
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2003). In mice, Tbdn and Ard1 are highly expressed during brain development in areas of 
cell division and migration and are downregulated as neurons differentiate (Sugiura et al., 
2003). However, high levels of Tbdn protein in adults are restricted to few vascular beds 
including blood vessels of regressing ovarian follicles and the ocular endothelium 
(Gendron et al., 2000;Gendron et al., 2001;Paradis et al., 2002).   
A mutation in the Ard1 gene which causes Ogden syndrome has been found to be 
lethal in human infant males. The disorder is comprised of a combination of symptoms 
including an aged appearance as well as prominent eyes (Rope et al., 2011). Another 
mutation in the Ard1 gene resulting in Lenz Micropthalmia Syndrome (LMS) which is 
characterized by anothalmia or micropthalmia also involves dysregulation of the STRA6 
gene (Esmailpour et al., 2014). STRA6 is a retinol binding protein receptor which 
mediates cellular uptake of  retinol and is important in regulating the retinoic acid 
signalling pathway (Kawaguchi et al., 2007). In LMS, expression array studies showed 
decreased expression of genes involved in the retinoic acid signalling pathway including 
STRA6 (Esmailpour et al.,2014). These studies indicate that different mutations in the 
Ard1 gene can have different effects. 
There is evidence that Tbdn plays a role in regulation of retinal homeostasis as 
well as in growth and differentiation. The Gendron/Paradis lab has characterized Tbdn as 
a novel homeostatic factor which has been shown to be involved in blood vessel growth 
and homeostasis (Gendron et al., 2000;Gendron et al., 2001;Paradis et al., 2002). An 
earlier study reports that Tbdn is found to be downregulated during capillary-like 
formation of IEM embryonic endothelial cells suggesting that it plays a role in dampening 
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blood vessel formation (Paradis et al., 2002). The knockdown of Tbdn expression in 
RF/6A rhesus macaque choroid-retina endothelial cells resulted in an increase in 
formation of capillary-like structures, supporting the idea that Tbdn negatively regulates 
angiogenesis (Paradis et al., 2002). Drs. Paradis and Gendron have created cell clones in 
which Tbdn levels are suppressed by expression of an antisense TDBN cDNA construct 
(Paradis et al., 2002). Knockdown of Tbdn using these clones resulted in co-suppression 
of Ard1 protein levels and increased permeability of FITC-Albumin across a cellular 
monolayer (Paradis et al., 2008). Drs. Paradis and Gendron have also created a 
bitransgenic mouse model that enables conditional knockdown of Tbdn in endothelial 
cells (Wall et al., 2004). These mice exhibited retinal and choroidal neovascularisation 
and intra- and preretinal fibrovascular lesions resembling those seen in human 
proliferative retinopathies (Wall et al., 2004). Conditional knockdown of Tbdn in 
endothelial cells of transgenic mice also resulted in retinal neovascularization and 
thickening and extravasation of albumin from retinal blood vessels in vivo (Paradis et al., 
2008). In addition, a study has found that endocytosis of β-amyloid precursor 
transmembrane protein can be inhibited by overexpression of the NatA complex (Tbdn 
and Ard1; (Asaumi et al., 2005). Tbdn has been found specifically suppressed in retinal 
blood vessels of neovascular retinal lesions of patients with AMD, PDR and ROP 
(Gendron et al., 2001;Gendron et al., 2006;Gendron et al., 2010;Paradis et al., 2002). 
Furthermore, Tbdn has been found to co-localize with Cortactin and Filamentous (F)-
actin in the cytoplasm and in the cortex of endothelial cells (Paradis et al., 2008). All of 
these studies together suggest that the NatA complex plays a role in regulation of 
endothelial cell permeability. 
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Figure 3: The molecular organisation of Tbdn and Ard1. 
Tbdn and Ard1 interact to form the NatA complex. Tbdn contains a series of TPR repeats 
while Ard1is the catalytic subunit of the NatA complex containing an acetyltransferase 
motif. 
 
1.6 Cortactin 
Tbdn has been found to colocalize with Cortactin and F-actin in cytoplasmic 
regions and at the cortex of endothelial cells (Paradis et al., 2008). Cortactin is an 80-85 
kDa cortical actin binding protein which is a substrate of viral Src (v-Src) transformed 
cells (Wu et al., 1991). Cortactin structure consists of an N-terminal acidic domain 
(NTA), six and a half tandem repeats, an α-helical region, a proline-rich region and a Src 
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homology (SH3) domain (Fig. 2). Cortactin is also known to regulate cellular 
permeability through its interaction with the actin cytoskeleton (Daly, 2004;Mehta and 
Malik, 2006).  Within the NTA domain, Cortactin has been shown to bind and activate 
actin-related protein (Arp) 2/3 which increases N-WASp (Wiskott-Aldrich syndrome 
protein) – mediated actin nucleation and polymerization (Ammer and Weed, 2008).  
Cortactin can be phosphorylated by cellular Src (c-Src), v-Src and Fyn on three 
separate residues (Tyr 421, Tyr 466 and Tyr 482). Phosphorylation of Cortactin at Tyr 
421 creates a binding site for c-Src which will result in phoshphorylation of Tyr 466 and 
Tyr 482 (Weed and Parsons, 2001). Increased phosphorylation of Cortactin by c-Src led 
to increased cellular migration and cancer metastasis (Ammer and Weed, 2008;Daly, 
2004;Huang et al., 1998). 
c-Src phosphorylation of Cortactin has been shown to regulate endocytosis 
through actin polymerization (Ammer and Weed, 2008). Tbdn has also been reported to 
colocalize with Cortactin at the cortex of endothelial cells (Paradis et al., 2008). 
Therefore, it would be beneficial to look into the interaction between the NatA complex 
and Cortactin phosphorylation in the Tbdn-mediated regulation of retinal endothelial 
permeability of albumin. 
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Figure 4: The molecular organisation of Cortactin.  
Arp2/3 binds the DDW-motif within the NTA domain. The actin-binding domain 
contains six-and-a-half tandem repeats. c-Src phosphorylation of Y421, Y466 and Y482 
occurs in the proline-rich region. 
 
 
1.7 Src Family Kinases 
Src family kinases are a family of non-receptor tyrosine kinases that includes nine 
kinases: c-Src, Fyn, Lyn, Blk, Yes, Lck, Hck, Fgr and Yrk. The Src family kinases play 
roles in regulation of cellular proliferation and cellular permeability and endocytosis 
(Dehm and Bonham, 2004;Mehta and Malik, 2006;Sverdlov et al., 2007). Specifically, 
the protein tyrosine phosphatase DEP-1 (density-enhanced phosphatase) is 
phosphorylated in a Src- and Fyn- dependent manner. This allows DEP-1 to 
dephosphorylate Src on its inhibitory residue Y529 and allows VEGF induced Src 
phosphorylation of VE-cadherin and Cortactin. Furthermore, knockdown of DEP-1 
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impairs Src-dependent VEGF-mediated responses including regulation of permeability 
and capillary formation (Spring et al., 2012). Another Src family kinase known as Lyn is 
expressed in B cells and has both positive and negative roles in B cell receptor induced 
signal transduction (Xu et al., 2005). 
v-Src is a gene found in Rous Sarcoma virus that produces a tyrosine kinase that 
causes cancer in chickens (Smart et al., 1981). c-Src, a 60kDa Src Family Kinase, has 
been reported to show increased activation in colon, liver, lung, breast and pancreatic 
cancers (Dehm and Bonham, 2004).  
c-Src contains a myristoylated N-terminus, a SH4 domain, a unique region, a SH3 
domain, a SH2 domain, a linker region, a catalytic domain (SH1) as well as a regulatory 
domain (Fig. 3).  In the inactive confirmation the SH2 domain of c-Src interacts with the 
Tyr 527 residue in the regulatory domain. Phosphorylation at the Tyr 416 residue in the 
catalytic domain changes c-Src to its active conformation in which it can phosphorylate 
its targets. Carboxy-terminal Src kinase (Csk) and protein tyrosine phosphatase 1 (PTP1) 
can phosphorylate and dephosphorylate Tyr 527 respectively while Tyr 416 undergoes 
autophosphorylation (Roskoski, 2005). v-Src lacks the Tyr 527 inhibitory residue and is 
therefore constitutively active as opposed to normal c-Src (Hunter and Cooper, 1985). 
c-Src also plays a role in regulation of transendothelial permeability of albumin. 
When albumin binds to the glycoprotein 60 receptor (gp60) it induces clustering of the 
receptor and activation of c-Src through βγ subunit of Gi. Activated c-Src then 
phosphorylates caveolin-1, the Guanosine triphosphate (GTP)ase dynamin-2 and the gp60 
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receptor in order to induce transendothelial vesicular transport of albumin through the cell 
(Mehta and Malik, 2006). The Caveolin-1 Tyr 14 residue is phosphorylated by Src to 
initiate caveolar invagination from the plasma membrane (Kim et al., 2009;Shajahan et 
al., 2004). Dynamin Tyr 597 was identified as an important residue phosphorylated by c-
Src responsible for caveolae-mediated endocytosis (Shajahan et al., 2004). Another 
known substrate of c-Src is Cortactin. c-Src has been reported to phosphorylate Cortactin 
and regulate endocytosis through actin polymerization (Ammer and Weed, 2008). 
Therefore, it would be beneficial to explore the possible relationship between the NatA 
complex, c-Src and phosphorylated Cortactin and their roles in Tbdn-mediated regulation 
of retinal endothelial permeability of albumin. 
 
Figure 5: The molecular organisation of c-Src.  
Src contains a myristoylation site, SH4 domain, unique region, SH3 domain, SH2 
domain, linker, catalytic SH1 domain and a regulatory domain. The two main 
phosphoryation sites are Y416 in the catalytic domain and Y527 in the regulatory domain.  
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1.8 Rationale Behind Current Study 
Many people around the world suffer from vision loss and other complications 
associated with AMD, PDR and ROP. These diseases involve neovascularisation and 
hyperpermeability of retinal blood vessels. Changes in endothelial permeability can result 
in leakage of plasma proteins such as albumin from the retinal blood vessels into the 
interstitial space, resulting in inflammation and vision loss. The Tbdn protein has been 
shown to regulate endothelial permeability in the retinal blood vessels (Gendron et al., 
2000; Gendron et al., 2001; Paradis et al., 2008; Gendron et al., 2010). Knockdown of 
Tbdn has been reported to lead to co-suppression of Ard1 protein levels. (Paradis et al., 
2008). Also, Tbdn is known to form the NatA complex with Ard1. c-Src phosphorylation 
of Cortactin regulates endocytosis through actin polymerization (Ammer and Weed, 
2008). This study will examine the effects of knockdown and overexpression of Ard1 on 
Tbdn, phosphorylated Cortactin Tyr 421 and phosphorylated c-Src Tyr 416 levels as well 
as permeability of retinal endothelial cells to albumin.  
Learning more about the role Tbdn/Ard1 plays in regulation of retinal endothelial 
cell permeability could possibly lead to development of drugs to treat those suffering 
from AMD, PDR and ROP. My hypothesis is that Tbdn-mediated regulation of retinal 
endothelial permeability requires the acetyltransferase Ard1.  
Aim 1: Examine the effect of Ard1 knockdown in RF/6A cells. 
Aim 2: Examine the effect of Ard1 overexpression in RF/6A cells. 
Aim 3: Examine the effect of knockdown of Ard1 and overexpression of Ard1 on 
permeability of RF/6A cells to albumin. 
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Chapter 2 Materials and Methods 
 
2.1 Cell Culture 
RF/6A retinal endothelial cell line (CRL-1780; American Type Culture 
Collection) from Macaca mulatta were grown in Dulbecco’s modified eagle medium 
(DMEM; Life Technologies Inc., Burlington, ON) supplemented with 10% fetal bovine 
serum (FBS) plus 2nM glutamine and nonessential amino acids. RF/6A cell clones in 
which Tbdn expression is suppressed by stable expression of the antisense Tbdn cDNA 
construct AS-TBDN were grown in DMEM  supplemented with 10% FBS, 2nM 
glutamate, nonessential amino acids and in the presence of zeocin (Life Technologies 
Inc., Burlington, ON). RF/6A TE2 #9 cell clones which overexpress Myc-tagged human 
ARD1 construct provided by Dr. Paradis (Faculty of Medicine, Memorial University of 
Newfoundland) were also grown in culture in DMEM  supplemented with 10% FBS, 
2nM glutamate, nonessential amino acids and in the presence of 750ug/100ml G418 (Life 
Technologies Inc., Burlington, ON) and analysed using permeability assays and western 
blot. All cells were cultured on 100mm tissue culture dishes and were maintained at 37°C 
in 10% CO2 atmosphere. The cells were counted by trypsinizing the cells followed by 
counting using a hemocytometer. 
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2.2 Antibodies 
Mouse monoclonal anti-Ard1 (sc-373920) and anti-NARG1 (sc-81643) were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal anti-
STAT3 (sc-482) was also obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 
Rabbit polyclonal anti-Phospho-Cortactin (Tyr421) antibody (#4569) and rabbit 
monoclonal anti-Phospho-Src Family (Tyr416) antibody (#6943) were obtained from Cell 
Signalling Technology (Danvers, MA). Other antibodies used included mouse 
monoclonal anti-Cortactin 4F11 (Millipore,  Billerica, MA), anti-c-Src clone 327 (Abcam, 
Toronto, ON) and anti-Fyn (sc-434; Santa Cruz, CA). Additional antibodies used 
included mouse monoclonal anti-α-tubulin DM1A (Sigma, St. Louis, MO). We used 
horseradish peroxidase (HRP) conjugated anti-mouse IgG and anti-rabbit IgG secondary 
antibodies for analysis by western blot (Promega, Madison, WI). 
 
2.3  Transfection 
Ard1 was knocked down using duplex siRNA corresponding to nucleotides 193-
211 of Macaca mulatta Ard1 cDNA within the coding region (5’-
CCAGAUGAAAUACUACUUCUU-3’) and scrambled control siRNA (5’-
ACUAACGUUACGUACAUCAUU-3’) which were purchased from Dharmacon (Fisher 
Scientific, Ottawa, ON). Macaca mulatta RF/6A cells were electroporated with 10nM 
concentrations of either control or Ard1 siRNA in addition to pmaxGFP vector obtained 
from Lonza (Basel, Switzerland). RF/6A cells were also transfected with 7.5ug/1.33 x 10
6
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cells of an Ard1-Myc/His Tagged expression vector pcDNA3.1 Neo –ARD1/MYC-HIS 
provided by Dr. Paradis (Faculty of Medicine, Memorial University of Newfoundland). 
The transfection was done using the Neon Transfection System (Life Technologies Inc., 
Burlington, ON) following the protocols specified by the manufacturer. The 
electroporated cells were then cultured at a density of 1.33 x 10
6
 cells/100 mm plate. 
After 48 hours, the cells were both plated for the permeability assay and plated for 
harvesting after an additional 24 hrs. Transfection efficiencies were determined by co-
transfecting the cells with a green fluorescent protein (GFP) plasmid followed by 
counting the number of fluorescent and total cells and expressing the transfection 
efficiencies as a percentage of fluorescent cells over total cells. 
 
2.4 Western Blot 
Protein extraction was performed as on cells allowed to grow for 24 hrs after 
being replated 48 hours post-transfection. Cells were washed twice with 25mM Tris pH 
7.6, 150nM NaCl, then harvested and suspended in cell lysis buffer (20mM Tris-HCl pH 
7.4, 10% glycerol, 137mM NaCl, 0.1% SDS, 1% Triton X100, 2mM EDTA, 0.5% Na 
Deoxycholate) which contains protease inhibitors (1mM phenylmethylsulfonyl fluoride, 
0.3 U/ml aprotinin and 10ug/ml leupeptin), phosphatase inhibitors (1mM sodium 
orthovanadate, 50mM sodium fluoride and 25mM β-glycerophosphate) and 1mM 
dithiothreitol. Lysates were clarified by centrifugation then a Bio-Rad protein assay was 
performed to determine protein concentration (Bio-Rad Laboratories, Hercules, CA). 
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Western blots were then performed by loading equal quantities of protein from the 
samples onto a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
followed by transfer to nitrocellulose membrane (GE Water & Process Technologies, 
Trevose, PA). Proteins were detected using specific primary and horseradish peroxidase 
conjugated secondary antibody. Western blotting analysis was completed using 
chemiluminescent detection by use of Lumiglo and ECL Advance chemiluminescent 
substrates (KPL, Inc., Gaithersburg, MD). Densitometry analyses were conducted using 
the Kodak Gel Logic 2200 imaging system (Eastman Kodak Company, Rochester, NY) 
and intensities of the bands were analyzed using Kodak Molecular imaging software 
(Version 4.0, Eastman Kodak Company, Rochester, NY). The bands were compared to 
loading controls and expressed as a percentage of non-transfected cells. At least 3 western 
blots were averaged per experiment. 
 
2.5 Transcellular Permeability Assay 
For fluorescein isothiocyanate (FITC)-Albumin permeability assays, RF/6A cells 
in which ARD1 has been knocked down by transfection with ARD1 siRNA were seeded 
onto transwell inserts (Costar Transwell, no. 3470, 6.5-mm diameter, 0.4-µm pore size; 
Corning, Tewksbury, MA) and grown in the same conditions as described in the cell 
culture section depending on the specific cell type. The assay was completed using cells 
transfected with 10nM ARD1 siRNA and 10nM Control siRNA and cells transfected with 
an Ard1-MYC-HIS overexpression vector. Permeability assays were also completed 
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using RF/6A parental cells and ASTBDN #20 cells. 40000 cells per insert (0.4 x 10
6 
cells/ml) were plated for transfected cells to account for cell death due to transfection 
while 30000 cells per insert (0.3 x 10
6 
cells/ml) were plated for non-transfected cells. The 
cells were grown to confluence on the inserts for 24 hours before being washed 3 times 
with DMEM. The integrity of the cellular monolayers were evaluated for confluence 
before use. The inserts were then transferred to new plates containing DMEM and 
incubated for 2 hours. FITC-albumin (Sigma A9771, Sigma, St. Louis, MO) was added at 
a final FITC-albumin concentration of 50uM. The rate of transit of FITC-albumin across 
the cell monolayer was determined by measuring the increase in the amount of FITC-
albumin in the lower well after 40 minutes of incubation. Using the FLUOstar optima 
spectrofluorometer (BMG LABTECH), fluorescence intensities were measured at an 
excitation wavelength of 485 nm and an emission wavelength of 520 nm and FITC-
albumin was quantified against a standard curve of FITC-albumin. Transcellular 
permeability assays and harvesting of cells for analysis by western blot were completed in 
parallel at 72 hours post transfection. 
 
2.6 Data and Statistical Analysis 
Statistical analysis of western blot protein quantitations were compared using the 
one-way analysis of variance (ANOVA), followed by the Fisher’s exact statistical test. 
The P values were calculated using PRISM program and the data was determined to be 
statistically significant if the P value was less than 0.05. 
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Chapter 3 Results 
 
 
3.1 Ard1 is significantly knocked down and overexpressed in RF/6A retinal 
endothelial cells. 
Tbdn has been shown to play a role in regulation of retinal endothelial cell 
permeability to albumin (Paradis et al., 2008). In addition, the effect of Tbdn in regulation 
of retinal endothelial cell permeability is supported by the role Tbdn plays in regulation of 
retinal homeostasis and neovascularisation (Wall et al., 2004). Furthermore, the role of 
Tbdn in the regulation of endocytosis (Asaumi et al., 2005), which is a necessary step in 
the transcellular permeability of albumin, indicates that Tbdn is involved in transcellular 
permeability regulation (Paradis et al., 2008). Therefore, it was only logical that we 
investigate the role of the other half of the NatA complex, Ard1, in regulation of the 
transcellular permeability of albumin. In order to examine the role of Ard1 in albumin 
permeability, we knocked down Ard1 in RF/6A cells. Furthermore, we transfected RF/6A 
cells with an Ard1 overexpression plasmid to analyse the effect of Ard1 overexpression 
on albumin permeability. For each experiment, transfection efficiencies were calculated 
for each plate of GFP transfected cells. The transfection efficiencies varied from a mean 
of 42% ± 9% for cells only transfected with GFP to 62% ± 2% for cells transfected with 
both the Ard1 vector and GFP (Fig. 6). There was no significant difference in the 
transfection efficiencies among the different groups of transfected cells. Ard1 was 
significantly knocked down by transient siRNA transfection of 10nM of Ard1 siRNA 
30 
 
when compared to non transfected, control siRNA transfected and GFP transfected cells 
(P < 0.01; Fig. 7B). Ard1 was also significantly overexpressed by transfection of RF/6A 
cells with Ard1 expression vector when compared to non transfected, control siRNA 
transfected and GFP transfected cells (P < 0.01; Fig. 7). Ard1 was overexpressed by 3.7 ± 
0.48 fold in RF/6A retinal endothelial cells when compared to GFP transfected cells (P < 
0.01; Fig. 7B) and by 1.4 fold in 10nM CTR siRNA transfected cells compared to GFP 
transfected cells and non transfected cells (P < 0.01; Fig. 7B).  
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Figure 6: Relative transfection efficiencies. 
Transfection efficiencies for control siRNA transfected cells (CTR), Ard1 siRNA 
transfected cells (Ard1), GFP transfected cells (GFP) and cells transfected with Ard 
overexpression plasmid (Ard1 vector). Transfection efficiencies were determined as a 
percentage of fluorescent cells over total cells. There was no significant difference in the 
transfection efficiencies between groups. Data shown is expressed as the mean ± s.e.m in 
each group (n=3). 
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Figure 7: siRNA-mediated knockdown of Ard1 and Ard1 overexpression in RF/6A 
retinal endothelial cells.  
Non transfected cells (NT), control siRNA transfected cells (CTR), Ard1 siRNA 
transfected cells (Ard1), cells transfected with Ard1 overexpression plasmid (Ard1 
vector) and GFP transfected cells (GFP) protein levels were analyzed by western blot for 
Ard1 expression. The blot was re-probed and analyzed for Stat3 as a loading control. The 
only groups that were not significantly different were NT and GFP. Ard1 was 
significantly knocked down by 10nM Ard1 siRNA (P < 0.01) when compared to NT, 
CTR and GFP.  Ard1 was significantly overexpressed by transfection with Ard1 
expression vector (P < 0.01) when compared to NT, CTR and GFP. (A) Representative 
experiment; (B) the average of Ard1 levels ± s.e.m. of experiments are shown (n=5). 
Ard1 protein levels in B are relative to loading controls and expressed as a percentage of 
non-transfected cells. 
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3.2 Ard1 knockdown and Ard1 overexpression have no effect on Tbdn levels. 
Knockdown of Tbdn in endothelial cells resulted in co-suppression of Ard1 
protein levels (Paradis et al., 2008). To investigate if Ard1 levels regulate Tbdn levels, we 
examined the effect of Ard1 knockdown and Ard1 overexpression on Tbdn levels. The 
results showed that the knockdown of Ard1 or the overexpression of Ard1 resulted in no 
significant effect on Tbdn levels in RF/6A retinal endothelial cells when compared to non 
transfected cells (Fig. 8). However, Tbdn levels of 10nM CTR siRNA transfected cells 
were found to be increased compared to 10nM Ard1 siRNA and GFP transfected cells by 
approximately 1.5 fold (P < 0.05; Fig. 8B). 
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Figure 8: Ard1 knockdown and Ard1 overexpression in RF/6A retinal endothelial 
cells has no effect on Tbdn levels.  
Non-transfected cells (NT), control siRNA transfected cells (CTR), Ard1 siRNA 
transfected cells (Ard1), cells transfected with Ard overexpression plasmid (Ard1 vector) 
and GFP transfected cells (GFP) protein levels were analyzed by western blot for Tbdn 
expression. The blot was re-probed and analyzed for Stat3 as a loading control. Ard1 
knockdown or overexpression resulted in no significant effect on Tbdn levels when 
compared to NT. (A) Representative experiment; (B) the average of Tbdn levels ± s.e.m. 
of experiments are shown (n=5). Tbdn protein levels in B are relative to loading controls 
and expressed as a percentage of non-transfected cell protein levels. (* is P < 0.05). 
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3.3 Transfection of RF/6A cells with Ard1 overexpression plasmid results in a 
significant decrease in the amount of cells at 48 hrs post-transfection. 
Transfection often produces increased levels of cell death. Knockdown and 
overexpression of genes and proteins by transfection can affect the number of cells 
present after transfection and both transfection as well as the aberrant expression of genes 
that can affect the post-transfection cell count. During this experiment, the cells of each 
cell type were counted at 48 hours post-transfection. The cell count of cells transfected 
with the Ard1 overexpression plasmid were significantly decreased when compared to 
non transfected, GFP transfected, 10nM Ard1 siRNA transfected and 10nM CTR siRNA 
transfected cells despite the fact that the same amount of cells were transfected at time 0 
(P < 0.05; Fig. 9). The cell count of cells transfected with the Ard1 overexpression 
plasmid was 51% lower than that of cells transfected with GFP (P < 0.05; Fig. 9).  
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Figure 9: Transfection of RF/6A cells with Ard1 overexpression plasmid results in a 
significant decrease in the amount of cells at 48 hrs post-transfection. 
Cells transfected with Ard1 vector have significantly lower cell counts than all other 
experimental groups (P < 0.05). Cell count 48 hrs after transfection of RF/6A cells with 
1.33 x 10
6
 cells per 100mm plate. Control siRNA transfected cells (CTR), Ard1 siRNA 
transfected cells (Ard1), GFP transfected cells (GFP) and cells transfected with Ard1 
overexpression plasmid (Ard1 vector) were all transfected with GFP. The average cell 
count ± s.e.m. of experiments are shown (n=3). Non transfected (NT) cells were plated at 
0.8 x 10
6
 cells per 100mm plate at the time of transfection to prevent the cells from being 
over confluent at 48 hrs. (* is P < 0.05). 
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3.4 Ard1 knockdown and Ard1 overexpression have no effect on phospho-Tyr421 
Cortactin levels. 
Cortactin has been shown to co-localize with Tbdn along the actin cytoskeleton 
and at the cortex of endothelial cells (Paradis et al., 2008).  Cortactin is also known to 
regulate cellular permeability through its interaction with the actin cytoskeleton (Daly, 
2004; Mehta and Malik, 2006). We examined the effects of Ard1 knockdown on 
phospho-Tyr421 Cortactin and total Cortactin levels. The levels of phospho-Tyr421 
Cortactin and total Cortactin were measured by western blotting techniques using specific 
antibodies. Ard1 knockdown by transient siRNA transfection or Ard1 overexpression 
resulted in no significant change in phospho-Tyr421 Cortactin over total Cortactin levels 
relative to loading controls (Fig. 10C).  
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Figure 10: Ard1 knockdown and Ard1 overexpression in RF/6A retinal endothelial 
cells has no significant effect on phospho-Tyr421 Cortactin levels.                         
Non-transfected cells (NT), control siRNA transfected cells (CTR), Ard1 siRNA 
transfected cells (Ard1), cells transfected with Ard overexpression plasmid (Ard1 vector) 
and GFP transfected cells (GFP) protein levels were analyzed by western blot for 
phospho-Tyr421 Cortactin and total Cortactin levels. The blot was re-probed for Stat3 as 
a loading control. Cortactin protein levels in C are relative to loading controls and 
expressed as a percentage of non-transfected cell protein levels. There was no significant 
difference between the groups. (A) Representative experiment for phospho-Tyr421 
Cortactin; (B) Representative experiment for total Cortactin (C) average of phospho-
Tyr421 Cortactin levels over total Cortactin levels ± s.e.m. of experiments are shown 
(n=3).  
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3.5 Ard1 knockdown has no effect on phospho-c-Src/Fyn levels while Ard1 
overexpression results in increased levels of phospho-c-Src/Fyn. 
We examined the effects of Ard1 knockdown and overexpression on c-Src protein 
levels. The tyrosine kinase c-Src has been reported to play a role in regulation of cellular 
permeability and caveolae-mediated endocytosis (Mehta and Malik, 2006;Shajahan et al., 
2004). Ard1 was knocked down as well as overexpressed in RF/6A cells and levels of 
phospho-c-Src/Fyn, total c-Src and total Fyn were analysed using western blotting 
techniques (Fig. 11A,C,E). Three bands were detected by western blot using the anti-
phospho-Src Family (Tyr416) antibody. The highest 60kDa band corresponds to activated 
c-Src and activated Fyn which co-migrate on the SDS-PAGE (Ho et al., 2012). The two 
lower bands represent the two isoforms of activated Lyn (Ho et al., 2012). Only the top 
band representing phosphorylated c-Src and phosphorylated Fyn was quantified. This 
study focuses on c-Src rather than Lyn levels due to the involvement of activated c-Src in 
the regulation of endothelial cell permeability (Mehta & Malik, 2006). Knockdown of 
Ard1 was found to have no significant effect on phospho-c-Src/Fyn levels relative to 
loading controls (Stat3 or Tubulin). However, Ard1 overexpression increased activated c-
Src/Fyn levels by 6 fold ± 0.7 fold compared to non transfected cells (P < 0.0001; Fig. 
10B). Knockdown and overexpression of Ard1 had no significant effect on total c-Src 
(Fig. 11D) or total Fyn levels (Fig. 11F). Phospho-c-Src/Fyn levels of 10nM CTR siRNA 
transfected cells were increased by 2.3 fold ± 0.32 fold compared to non-transfected cells 
(P < 0.05; Fig. 11B). Total c-Src levels of 10nM CTR siRNA transfected cells were 
increased by 1.3 fold compared to GFP transfected cells (P < 0.05; Fig. 11D). 
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Figure 11: Ard1 knockdown has no effect on phospho-c-Src/Fyn levels while Ard1 
overexpression results in increased levels of phospho-c-Src/Fyn. 
Non-transfected cells (NT), control siRNA transfected cells (CTR), Ard1 siRNA 
transfected cells (Ard1), cells transfected with Ard1 overexpression plasmid (Ard1 
vector) and GFP transfected cells (GFP) protein levels were analyzed by western blot for 
phospho-c-Src and phospho-Fyn (phospho-c-Src/Fyn) levels, total Src levels and total 
Fyn levels. The blots were re-probed for Stat3 as a loading control. Ard1 overexpression 
resulted in a significant increase in phospho-c-Src/Fyn levels (P < 0.0001) when 
compared to NT, CTR and GFP. Protein levels in B,D and F are relative to loading 
controls and expressed as a percentage of non-transfected cell protein levels. (A) 
Representative experiment for phospho-c-Src/Fyn. (B) average of Phospho-c-Src/Fyn 
levels ± s.e.m. of experiments are shown (n=3). (C) Representative experiment for total 
Src. (D) average of total c-Src levels ± s.e.m. experiments are shown (n=4). (E) 
Representative experiment for total Fyn. (F) average of total Fyn levels ± s.e.m. of  
experiments are shown (n=3). (* is P < 0.05). 
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3.6 Ard1 knockdown in RF/6A cells results in a decrease in albumin permeability 
while Ard1 overexpression results in an increase in albumin permeability. 
Transcellular permeability assays were performed to determine the effect of Ard1 
knockdown and Ard1 overexpression on permeability (Fig. 12). As shown in Fig. 12A, 
when Ard1 was knocked down, a significant decrease in permeability of retinal 
endothelial cells to albumin was observed when compared to controls (P < 0.05). 
Specifically, Ard1 knockdown reduced permeability of retinal endothelial cells to 
albumin by 20% ± 3% when compared to non transfected cells (P < 0.05), by 17% ± 3% 
when compared to control siRNA transfected cells (P < 0.05), and by 9% ± 4% when 
compared to GFP transfected cells (P < 0.05). However, when Ard1 is overexpressed, 
there was a significant increase in permeability of retinal endothelial cells to albumin 
when compared to controls (P < 0.01; Fig. 12B). Specifically, Ard1 overexpression 
increases the permeability of retinal endothelial cells to albumin by 21% ± 5% when 
compared to non transfected cells (P < 0.01) or by 33% ± 6% when compared to GFP 
transfected cells (P < 0.01). Knockdown of Tbdn levels using Tbdn knockdown clones 
resulted in an increase in permeability of 30% ± 4% of retinal endothelial cells to albumin 
when compared to non-transfected cells (P < 0.0001; Fig. 12B) or by 38% ± 4% when 
compared to GFP transfected cells (P < 0.0001). This is in agreement with data that has 
been described previously (Paradis et al., 2008).  Permeability of GFP transfected cells 
was slightly decreased by 12% ± 4% compared to non-transfected cells (P < 0.05; Fig. 
12B). 
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Figure 12: Ard1 knockdown in RF/6A cells results in a significant decrease in 
albumin permeability while Ard1 overexpression results in a significant increase in 
albumin permeability. 
FITC-albumin transit across monolayers of non-transfected cells (NT), control siRNA 
transfected cells (CTR), Ard1 siRNA transfected cells (Ard1), GFP transfected cells 
(GFP), cells transfected with Ard overexpression plasmid (Ard1 vector) and Tbdn-
knockdown clone (ASTBDN) were expressed as a percentage of NT cells after 40 
minutes. (A) Significantly lower percentages of FITC-albumin transit were observed in 
Ard1 knockdown cells than NT, CTR and GFP (P < 0.05).  (B) Significantly higher 
percentages of FITC-albumin transit were observed in Ard1 vector cells and ASTBDN 
cells when compared to NT and GFP (P < 0.01). FITC-Albumin transit across RF/6A 
monolayers is expressed as a percentage of non-transfected cells at 40 minutes. Data 
shown is expressed as the mean ± s.e.m. of experiments in each group (n=4). (* is P < 
0.05). 
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Chapter 4 Discussion 
 In order to understand the possible role of Ard1 in regulation of retinal endothelial 
permeability, we examined the link between Ard1 and known proteins involved in 
regulation of transcellular permeability of albumin. These proteins are Cortactin and c-
Src. Ard1 is an N-terminal acetyltransferase known to be involved in regulation of cell 
growth and differentiation of neuronal tissues (Arnesen et al., 2006;Lim et al., 2006;Lim 
et al., 2008;Sugiura et al., 2003). Acetylation is defined as the transfer of acetyl groups 
from acetyl coenzyme A (acetyl CoA) onto the ε amino acid groups of lysine residues 
which alters the biological properties of proteins (Deribe et al., 2010). This study focused 
on the relationship between Ard1 and phosphor-Tyr421 Cortacin and activated c-Src. 
Interestingly, results by the Gendron/Paradis lab reported that knockdown of Tbdn which 
is associated with a 50% reduction in Ard1 expression, results in increased levels of 
phospho-Tyr421 Cortactin and phospho-Tyr416 activated c-Src/Fyn levels and increases 
permeability to albumin. Therefore, we hypothesized that Tbdn regulation of retinal 
endothelial permeability requires Ard1.  
 In order to test this hypothesis, I knocked down and overexpressed Ard1 in RF/6A 
primate retinal endothelial cells using transient transfection techniques. There was no 
significant change in the transfection efficiencies of the cells transfected with either Ard1 
siRNA or Ard1 overexpression vector when compared to controls (Fig. 6). However, 
there was a significant decrease in the cell count of cells transfected with the Ard1 
overexpression vector when compared to controls (Fig. 9). A possible explanation for the 
reduced cell count is that overexpression of Ard1 in RF/6A cells results in an increase in 
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cell death following transfection. There are several different processes involved in death 
of cells which include apoptosis, senescence and necrosis. The most likely cause of cell 
death is an increase in apoptosis due to gene changes caused by overexpression of Ard1. 
Increased levels of Ard1 may alter the normal apoptotic pathways in the cells. 
Knockdown of Ard1 triggers apoptosis in human cell lines (Arnesen, Gromyko et al., 
2006). Furthermore, in lung cancer cells, knockdown of Ard1 results in reduced cyclin D1 
expression and suppressed cellular proliferation (Lim, Park, & Chun, 2006). However, 
breast cancer cell lines which overexpress Ard1 showed reduced cell growth (Kuo et al., 
2010). In addition, knockdown of Ard1 was shown to have no effect on cell count 
following transfection of RF/6A cells with Ard1 siRNA. It seems that overexpression of 
Ard1 in this experiment resulted in an increase in cell death following transfection. 
However, knockdown of Ard1 did not reduce the cell number and does not appear to lead 
to cell death in retinal endothelial cells. Ard1 appears to have different roles in regulation 
of cell death depending on the cellular context studied. The next logical step for future 
experiments would be to explore the role of Ard1 in regulation of apoptosis and cell death 
in retinal endothelial cells which is beyond the scope of this MSc thesis. 
Past research has shown that knockdown of Tbdn resulted in an increase in 
activated c-Src/Fyn levels and phospho-Tyr421 Cortactin levels (Ho, 2012). Research  by 
Drs. Gendron and Paradis has also shown that knockdown of Tbdn results in co-
suppression of Ard1 levels to approximately 50% and increased permeability of retinal 
endothelial cells to albumin (Paradis et al., 2008). However, knockdown of Ard1 by 
approximately 75% resulted in a small decrease in permeability of retinal endothelial cells 
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to albumin (Fig.12). The results suggest that Tbdn knockdown-mediated increase in 
permeability is either independent of Ard1 levels or is overcoming the effect of Ard1 
suppression to 50%. It is possible that the 50% Ard1 knockdown resulting from Tbdn 
knockdown might be a feedback response of the cells to Tbdn knockdown in order to re-
establish the normal permeability. On the other hand, overexpression of Ard1 resulted in 
a significant increase in activated c-Src/Fyn levels (Fig. 11) as well as an increase in 
permeability of retinal endothelial cells to albumin (Fig. 12). All together these studies 
indicate that Tbdn decreases permeability while Ard1 increases it. However, the role of 
Ard1 on c-Src/Fyn and Cortactin regulation is less clear. Past results have shown that 
knockdown of Tbdn resulted in an increase in activated c-Src/Fyn levels and phospho-
Tyr421 Cortactin levels (Ho, 2012). My results revealed no significant change in the 
levels of phosphorylated Cortactin (Y421) or activated c-Src/Fyn associated with the 
knockdown of Ard1 (Fig. 10, Fig. 11). It is possible that the effects of  Ard1 knockdown 
on these two components of the albumin permeability pathway are too minimal to be 
observed under the tested conditions. In addition, the results suggest that Ard1-mediated 
increase of activated Src/Fyn does not require Tbdn. Overexpression of Ard1 was not 
associated with an increase in Y421-Phospho-Cortactin levels. This could suggest that 
Tbdn is required to regulate Y421-phospho-Cortactin levels or alternatively that the 
effects of Ard1 overexpression on Y421-Phospho-Cortactin are too minimal to be 
observed under the tested conditions. Overexpression of Ard1 might alter endothelial 
albumin permeability via a mechanism that differs from Tbdn knockdown in that it does 
not involve phosphorylation of Cortaction but may involve c-Src activation. It is also 
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possible that the co-suppression of Ard1 during Tbdn knockdown might oppose the 
decrease in permeability observed under such circumstances. 
 The mechanisms by which Ard1 regulates permeability are not clear. Ard1 
knockdown has been reported to result in increased apoptosis (Arnesen, Gromyko et al., 
2006). Moreover, both Ard1 and Tbdn are known to play roles in cell growth (Arnesen et 
al., 2006;Asaumi et al., 2005;Lim et al., 2006;Park and Szostak, 1992). Knockdown and 
overexpression of Ard1 could cause abnormal regulation of cell growth or apoptosis 
depending on the cellular context. Src family kinase members Fyn and Lyn are cleaved in 
their unique region in hematopoietic cells undergoing apoptosis (Luciano et al., 2001). 
This could result in changes in permeability of retinal endothelial cells to albumin in 
response to changes in Ard1 levels since the Src family kinases c-Src and Fyn have been 
shown to be involved in regulation of permeability (Gong et al., 2008). One possible 
explanation for the increase in phosphorylated c-Src/Fyn and increase in permeability 
could be in relation to the active site of Ard1. A study has shown that the binding of Tbdn 
to Ard1 to form the NatA complex causes a structural change in the active site of Ard1 
which allows it to acetylate different targets than when Ard1 is not in complex with Tbdn 
(Liszczak et al., 2013). When Ard1 is overexpressed, more Ard1 may exist on its own 
rather than in complex with Tbdn creating a structurally different active site which can 
acetylate different targets than when Tbdn is bound to Ard1. It is possible that Ard1 can 
acetylate different targets when not bound to Tbdn, which could provide an alternate 
mechanism of regulation of permeability of retinal endothelial cells to albumin.  
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Tbdn levels of 10nM CTR siRNA transfected cells were found to be significantly 
higher than 10nM Ard1 siRNA transfected cells (Fig. 7). Furthermore, Ard1 levels of 
10nM CTR siRNA transfected cells were found to be significantly higher than GFP 
transfected cells and non-transfected cells (Fig. 6). Phosphorylated c-Src/Fyn levels of 
10nM CTR siRNA transfected cells were also found to be significantly higher than non-
transfected cells (Fig. 10). Transfection with this specific CTR siRNA is somehow 
increasing Tbdn and Ard1 levels. When the CTR siRNA was ordered, the siRNA 
sequence was entered into a nucleotide blast to determine if there was any homology to 
any proteins other than Ard1. When designing the scrambled CTR siRNA, sequences 
with more than 14 contiguous base pairs of homology to other coding sequences were 
excluded. Although the program BLAST was used to compare the CTR siRNA to both 
human and macaca mulatta genomes, it is possible that the CTR siRNA is knocking 
down another protein that could result in the increased levels of Tbdn and Ard1. To 
overcome this problem, the experiment could be completed with a different scrambled 
CTR siRNA to see if the effects on Tbdn and Ard1 levels are repeated. Permeability 
analysis also showed that permeability of GFP transfected cells was significantly 
decreased compared to non-transfected cells. It is also possible that the transfection 
process itself might affect the permeability to albumin. 
Further research is required to determine the role of Ard1 in regulation of retinal 
endothelial cell permeability. Possible future directions could include overexpression of 
Tbdn to then observe the effects on Ard1 levels, activated c-Src levels and permeability. 
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Chapter 5 Conclusions 
This study examined the effects of knockdown and overexpression of Ard1 on 
Tbdn, phosphorylated Cortactin Tyr 421 and phosphorylated c-Src Tyr 416 levels as well 
as permeability of retinal endothelial cells to albumin. Previous work in the laboratory of 
Drs. Gendron and Paradis have shown Tbdn to be involved in regulation of retinal 
endothelial permeability (Paradis et al., 2008). 
The results revealed that knockdown of Ard1 resulted in a decrease in 
permeability of retinal endothelial cells to albumin, however had no effect on phospho-c-
Src/Fyn or phosphorylated Cortactin Tyr 421 levels. Overexpression of Ard1 resulted in 
increased levels of phospho-c-Src/Fyn and increased permeability of retinal endothelial 
cells to albumin. This suggests that Ard1 overexpression may alter endothelial albumin 
permeability through a pathway which does not involve phosphorylation of Cortactin but 
may involve c-Src activation.  
It appears that the relationship between Ard1 and permeability is more 
complicated than expected and will require further study. Understanding more about the 
role of Ard1 and Tbdn in the regulation of retinal endothelial permeability could lead to 
development of drugs to help treat those suffering from neovascular retinopathies. 
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